Arca
Skip to content
Tools
Tools

Psychosis

Drug research and approvals for psychosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 439 studies of psychosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 439
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 439 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,543 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 328 whose ending is known, 51% met their primary endpoint, 9% missed it and 39% stopped early.

  • Completed, result not reported72947%
  • Ongoing31921%
  • Met its primary endpoint16811%
  • Status unknown16711%
  • Stopped: other or unclear705%
  • Stopped: enrollment or feasibility342%
  • Missed its primary endpoint312%
  • Stopped: funding111%
  • Stopped: sponsor or business decision7<1%
  • Stopped: lack of efficacy5<1%
  • Stopped: safety2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Apr 7, 2026A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of karxt + karx-ec for the treatment of…Xanomeline-trospium (BMS-986510) / Xanomeline (BMS-986519)Bristol-Myers SquibbPending
Feb 4, 2025A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ML-007C-ma for the treatment of hallucinations and delusions…ML-007C-MAMapLight TherapeuticsOngoing
May 28, 2024Open-label extension study to assess the long-term safety and tolerability of karxt in subjects with psychosis associated with Alzheimer's diseaseXanomeline-trospium (KARXT)Bristol-Myers SquibbClosed
Jan 8, 2024A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of karxt for the treatment of psychosis…Xanomeline-trospium (KARXT)Bristol-Myers SquibbOngoing
Aug 4, 2022Longitudinal assessment of synaptic density across the psychosis spectrum using the novel synaptic vesicular protein 2a tracer [18f]synvest-1[18F] SDM-8 injCentre for Addiction and Mental HealthOngoing
Aug 20, 2021Investigating synaptic density in youth at risk for psychosis using the pet tracer [F-18]synvest-1 ([F-18]SMD8[F-18] SDM-8Centre for Addiction and Mental HealthOngoing
Aug 1, 2018Imaging nociceptin receptors in clinical high risk and first episode psychosis using positron emission tomography with the novel radioligand [11c]NOP-1A[11C]-NOP-1APet Centre Centre for Addiction and Mental HealthClosed

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Jul 25, 2008MetyrosineTreatment of velocardiofacial syndrome associated psychosis.Cerberus Princeton, LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.